Condition
Hemoperfusion
Total Trials
4
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Completed3
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05044403Not ApplicableRecruitingPrimary
Hemoperfusion in Critical Patients With Septic Multiorgan Dysfunction Syndrome.
NCT04643639Phase 3Completed
Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis
NCT02461953Not ApplicableCompleted
Combination of Hemodialysis With Hemoperfusion：A Clinical Study
NCT03487146Not ApplicableCompletedPrimary
HP Improves Sleep and Overall Survival Rate in Maintenance Hemodialysis Patients
Showing all 4 trials